# Human Meningiomas Reveal No Evidence of Neuroendocrine Differentiation

**Authors:** Sofie Eline Tollefsen, Anders Hagen Jarmund, Ole Solheim, Ida Kaalhus Nordahl, Thi My Linh Hoang, Anette H. Skjervold, Patricia Mjønes, Sverre Helge Torp

PMC · DOI: 10.1111/apm.70177 · Apmis · 2026-03-02

## TL;DR

This study finds no evidence that meningiomas, a type of brain tumor, have neuroendocrine features, despite some similarities to neuroendocrine tumors.

## Contribution

The study provides new evidence against neuroendocrine differentiation in meningiomas using multiple immunohistochemical markers and electron microscopy.

## Key findings

- NSE was detected in 91% of meningiomas, but other neuroendocrine markers like chromogranin A and synaptophysin were mostly absent.
- No secretory granules were detected in meningioma specimens using transmission electron microscopy.
- NSE and chromogranin B showed correlations with SSTR2 immunoreactivity and varied by tumor grade and subtype.

## Abstract

Meningiomas are heterogeneous tumors and studies suggest that meningiomas might be part of MEN1 syndrome. The tumors express somatostatin receptors (SSTRs) comparable to that seen in neuroendocrine neoplasms. We aimed to explore neuroendocrine differentiation in meningiomas by investigating the following neuroendocrine markers: neural cell adhesion molecule (CD56/NCAM), chromogranin A, chromogranin B, chromogranin C, neuron‐specific enolase (NSE), secretagogin, and synaptophysin. Our findings were related to WHO grade, tumor subtype, and SSTR2 immunoreactivity. Tissue microarrays from 162 patients with intracranial meningioma underwent immunohistochemical analyses. Immunoreactivity was assessed with manual and digital analyses. Transmission electron microscopy (TEM) was used to detect secretory granules in one tumor specimen. NSE, CD56, and chromogranin B were detected in 91%, 44%, and 16% of meningiomas, respectively. The other neuroendocrine markers were mostly negative. NSE immunoreactivity was higher in WHO grade 2 tumors (p = 0.027) and differed among subtypes with highest and lowest immunoreactivity in meningothelial and fibrous subtypes, respectively. Chromogranin B (p = 0.006) and NSE (p = 0.003) were positively correlated to SSTR2 immunoreactivity. No secretory granules were detected. Manual and digital evaluation showed excellent agreement. Our study does not support the hypothesis of neuroendocrine differentiation in meningiomas, as chromogranin A and synaptophysin were mostly absent.

## Linked entities

- **Proteins:** NCAM1 (neural cell adhesion molecule 1), SSTR2 (somatostatin receptor 2)
- **Diseases:** MEN1 syndrome (MONDO:0007540), meningioma (MONDO:0003057)

## Full-text entities

- **Genes:** NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, CHGB (chromogranin B) [NCBI Gene 1114] {aka SCG1}, ENO2 (enolase 2) [NCBI Gene 2026] {aka HEL-S-279, NSE}, SCGN (secretagogin, EF-hand calcium binding protein) [NCBI Gene 10590] {aka CALBL, DJ501N12.8, SECRET, SEGN, setagin}, SSTR2 (somatostatin receptor 2) [NCBI Gene 6752] {aka SST2}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, SYP (synaptophysin) [NCBI Gene 6855] {aka MRX96, MRXSYP, XLID96}, CDKN2B (cyclin dependent kinase inhibitor 2B) [NCBI Gene 1030] {aka CDK4I, INK4B, MTS2, P15, TP15, p15INK4b}, SCG2 (secretogranin II) [NCBI Gene 7857] {aka CHGC, EM66, SN, SgII}, PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, CHGA (chromogranin A) [NCBI Gene 1113] {aka CGA, PHE5, PHES}, INSM1 (INSM transcriptional repressor 1) [NCBI Gene 3642] {aka IA-1, IA1}, MEN1 (menin 1) [NCBI Gene 4221] {aka MEAI, SCG2}
- **Diseases:** prostate cancer (MESH:D011471), DS (MESH:C000721267), gliomas (MESH:D005910), undifferentiated carcinomas (MESH:D002277), adenocarcinomas (MESH:D000230), 2 tumors (MESH:D009369), hyperprolactinemia (MESH:D006966), hemorrhage (MESH:D006470), medulloblastomas (MESH:D008527), PitNETs (MESH:D018358), Meningioma (MESH:D008579), MEN1 syndrome (MESH:D018761), CNS tumors (MESH:D016543), gastrointestinal neuroendocrine neoplasms (MESH:D005770), lymphomas (MESH:D008223), breast cancer (MESH:D001943), TMA (MESH:D017695), brain tumors (MESH:D001932), necrosis (MESH:D009336)
- **Chemicals:** phosphate (MESH:D010710), osmium tetroxide (MESH:D009993), Paraffin (MESH:D010232), ethanol (MESH:D000431), hematoxylin (MESH:D006416), Epon resin (-), uranyl acetate (MESH:C005460), Acetone (MESH:D000096), glutaraldehyde (MESH:D005976), potassium ferrocyanide (MESH:C031835), DAB (MESH:C000469)
- **Species:** Canis lupus familiaris (dog, subspecies) [taxon 9615], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12951546/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12951546/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12951546/full.md

---
Source: https://tomesphere.com/paper/PMC12951546